2025-08-14 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc (TMDX) based on the provided data, formatted for a report in English.

## Transmedics Group Inc (TMDX) Stock Analysis

**Company Overview:** Transmedics Group Inc is a medical technology company pioneering a novel approach to organ preservation for transplantation.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (TMDX):** 265.50%
*   **Cumulative Return (VOO):** 75.14%
*   **Absolute Spread:** 144.6
*   **Relative Spread Percentile:** 58.6 (This means the current spread is in the 58.6th percentile of its historical range.)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the tracked period. The relative spread percentile suggests that while the outperformance is substantial, it's not at the very highest end of its historical range, indicating there may be room for further growth, but also increased risk of reversion.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta | Cap(B) |
|------------|---------|--------|----------|------|--------|
| 2019-2021  | -4.0%  | 63.4%  | -52.0%   | 0.1  | 0.7    |
| 2020-2022  | 140.0% | 68.3%  | 133.0%  | 2.1  |        |
| 2021-2023  | 95.0%  | 69.4%  | 75.0%   | 2.7  |        |
| 2022-2024  | 147.0% | 82.8%  | 120.0%  | 2.1  |        |
| 2023-2025  | 147.0% | 82.8%  | 95.0%   | 4.5  |        |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR shows very strong growth over the more recent periods.
*   **MDD (Maximum Drawdown):** The MDD is quite high, indicating significant volatility and potential for substantial losses during downturns.
*   **Alpha:** Positive and very high alpha values suggest the stock significantly outperforms its benchmark on a risk-adjusted basis.
*   **Beta:** The beta values are high (above 1), indicating that the stock is more volatile than the market.  The increasing Beta values from 2019-2021 to 2023-2025 indicates that TMDX's volatility relative to the market has increased.

### 2. Recent Price Action

*   **Current Price:** \$132.04
*   **Previous Close:** \$131.13
*   **Change:** + \$0.69
*   **5-day Moving Average:** 124.20
*   **20-day Moving Average:** 115.39
*   **60-day Moving Average:** 124.32

**Analysis:** The current price is above all three moving averages, which generally suggests an upward trend.  The 5-day moving average is above the 20-day moving average, which is also a bullish signal. The stock price increased slightly over the previous day, reflecting a continuing upward trend.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3234 (Low Risk)
*   **RSI:** 71.10 (Overbought territory)
*   **PPO:** 2.06
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** -5.9 (Negative - Short-term decline)
*   **Expected Return:** 65.9% (Long-term)

**Analysis:**

*   The **MRI** indicates a low-risk environment, which is positive.
*   The **RSI** being above 70 suggests the stock is overbought and may be due for a correction.
*   The **PPO** (Percentage Price Oscillator) is positive, indicating a bullish trend.
*   The **Hybrid Signal** suggests a buy signal with 80% of available cash (or a small allocation of 1 share). It also mentions caution due to the MRI of 0.33.
*   The **negative Delta_Previous_Relative_Divergence** indicates short-term downward pressure on the stock price.
*   The **expected return** of 65.9% is very high, suggesting substantial long-term potential, but it's important to remember this is a projected return and not guaranteed.

Given the small price change from the previous close (+ \$0.69), there isn't a significant volatility event to note.

### 4. Recent News & Significant Events

*   **2025-08-14:** Major business developments, regulatory changes, or market events impacting Transmedics.
*   **2025-08-13:** Analyst discussions on Transmedics' performance and outlook, considering industry trends and global economic factors.
*   **2025-08-12:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-08-10:** Market experts highlighting risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The recent news suggests the company is experiencing significant activity and attention. The volatility mentioned warrants close monitoring.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-07-30 | 0.92  | 0.48     |
| 2025-05-08 | 0.7   | 0.29     |
| 2025-02-27 | 0.19  | 0.22     |
| 2024-10-28 | 0.12  | 0.29     |
| 2024-07-31 | 0.35  | 0.21     |

**Analysis:** TMDX has consistently beat EPS estimates in recent quarters. This indicates strong financial performance and suggests positive investor sentiment. The most recent earnings report (2025-07-30) showed a substantial beat, which likely contributed to recent price appreciation.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | \$0.16B    | 61.38%        |
| 2025-03-31 | \$0.14B    | 61.47%        |
| 2024-12-31 | \$0.12B    | 59.21%        |
| 2024-09-30 | \$0.11B    | 55.94%        |
| 2024-06-30 | \$0.11B    | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE      |
|------------|------------|----------|
| 2025-06-30 | \$0.32B    | 10.97%   |
| 2025-03-31 | \$0.27B    | 9.64%    |
| 2024-12-31 | \$0.23B    | 3.00%    |
| 2024-09-30 | \$0.21B    | 2.01%    |
| 2024-06-30 | \$0.19B    | 6.42%    |

**Analysis:**

*   **Revenue:** Revenue is steadily increasing quarter over quarter, demonstrating strong growth.
*   **Profit Margin:** The profit margin is consistently high, indicating good operational efficiency.
*   **Equity:** Equity is also increasing, which is a positive sign of financial health.
*   **ROE (Return on Equity):** ROE has fluctuated but is generally increasing, suggesting the company is becoming more efficient at generating profits from shareholder equity.

### 7. Overall Summary

Transmedics Group Inc (TMDX) shows strong financial performance and high growth potential, driven by consistent earnings beats and increasing revenue and profitability. The stock has significantly outperformed the S&P 500. However, it also exhibits high volatility (high Beta and MDD). The RSI indicates the stock is overbought, suggesting a potential short-term correction. The long-term expected return is very high, but this should be considered within the context of the company's volatility. The recent news warrants monitoring for any significant developments.

**Investment Recommendation:**

The hybrid signal recommends buying 80% of available cash with a cautionary note and a low MRI. Given the overbought RSI, the negative short-term delta, and the significant increase in Beta values and volatility, investors should proceed with caution. A reasonable strategy might be to scale into the position, starting with a smaller allocation and adding more shares on pullbacks.

**Disclaimer:** This is an analysis based on the provided data and should not be considered financial advice. Conduct thorough research and consult with a financial professional before making investment decisions.
